Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Date:2/19/2009

ly Chain Initiative. Excluding this item, Generic gross profit was $618.3 million, or 41.9 percent of revenue in 2008.


    Brand Segment Information

                                       Three Months Ended  Twelve Months Ended
                                           December 31,       December 31,
    (Unaudited; $ in thousands)           2008     2007      2008      2007
    Brand Segment Contribution
        Product sales                   $102,269  $94,106  $397,025  $375,202
        Other revenue                     13,442   15,232    57,953    53,520
      Net revenue                        115,711  109,338   454,978   428,722
      Cost of sales                       24,912   25,814   107,079    99,913
        Gross profit                      90,799   83,524   347,899   328,809
        Gross margin                       78.5%    76.4%     76.5%     76.7%

      Research and development            11,809   10,435    50,904    42,367
      Selling and marketing               31,605   28,664   118,198   108,061
        Segment contribution             $47,385  $44,425  $178,797  $178,381
        Segment margin                     41.0%    40.6%     39.3%     41.6%

Brand product sales for the fourth quarter of 2008 increased $8.2 million or 9 percent to $102.3 million, primarily due to increased sales of Specialty products. Brand other revenue decreased $1.8 million to $13.4 million.

Gross margin for the Brand segment increased from 76.4 percent in the fourth quarter 2007 to 78.5 percent in the fourth quarter 2008, reflecting a more favorable product mix.

For the full year 2008, Brand segment product sales increased 6 percent or $21.8 million to $397.0 million, compared to $375.2 million for 2007, due primarily to increased sales of Trelstar(R). Brand other revenue increased $4.4 million to $58.0 million.

Brand segment gross margin for 2008 was 76.5%, cons
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
2. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
3. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
4. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
5. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
6. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
7. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
8. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
9. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
10. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
11. Watson Pharmaceuticals Reports Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... roles two proteins, thrombospondin-1 and prosaposin, play in ... identified a five-amino acid fragment of prosaposin that ... prostate, breast and lung cancer. The findings suggest ... in a variety of cancers. , The ... Boston Children,s Hospital, Vivek Mittal, PhD, at Weill ...
(Date:5/21/2013)... the removal of the adenoids and tonsils, is performed ... as a treatment for children with obstructive sleep apnea. ... attention and executive functioning, behavior, sleep apnea symptoms, and ... now. A study led by Susan Redline, MD, ... Cardiovascular Medicine and Associate Clinic Director of the Division ...
(Date:5/21/2013)... Harbor, Florida (PRWEB) May 21, 2013 ... agency, announced today that they have redesigned their website ... a nude beach, pool, hot tubs, bars and dining. ... this nudist resort including sales and guest reviews, will ... island of Jamaica itself, including pages on culinary local ...
(Date:5/21/2013)... The American Diabetes Association ( http://goo.gl/YRSF1 ... United States of America are affected with peripheral neuropathy. ... risk of developing peripheral neuropathy which unfortunately makes it ... further goes on saying that the disease usually affects ... million new cases are diagnosed every year in the ...
(Date:5/21/2013)... Aggressive treatment for prostate cancer may not be ... conditions, a new study finds. Treatments for ... seed implants, can cause serious side effects, such ... explained researchers from the University of California, Los ... patients with slower growing forms of prostate cancer ...
Breaking Medicine News(10 mins):Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2
... Two Chinese soybean lines that grow without the primary ... have been isolated by scientists//. ,The two lines ... given away to breeders seeking to produce new varieties ... scientists at the University of Illinois at Urbana-Champaign and ...
... into action by mutations of the virus into a human flu ... what plan of action can we rely on to control the ... countries are teaming up next month to roll out a mock ... a pandemic. ,Australia and Singapore will be co-coordinating the ...
... of the out of hours health care system in England as ... ,The public accounts committee claimed that the new health care ... many key targets. ,In 2004 most GPs had opted ... PCTs took over in 90% of cases. ,The NAO ...
... plans for slow suffocation of millions of poultry, in ... ,According to Compassion in World Farming (CIWF) ... have been amended under emergency procedures whereby the Secretary ... a method of culling poultry in the event of ...
... a type 1 diabetic has been reported missing in West ... of medication// leaving her gravely ill, police have appealed for ... home in Uphall, at 2 pm on Monday. Stephanie went ... in Livingston. She is white, 5 ft 2in, of stocky ...
... University in Scotland found that women with high levels ... following in vitro fertilization. They found that the supplement ... after fertility treatment. ,However, the researchers said ... birth defects such as spina bifida, does not affect ...
Cached Medicine News:Health News:Promise for Soya Allergy Sufferers 2Health News:High Levels Of Folic Acid May Increase The Chances Of Twins After IVF 2
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... -- U.S. spending on specialty prescription drugs — those ... multiple sclerosis and rheumatoid arthritis — is projected to ... to a forecast released today by Express Scripts (NASDAQ: ... "As we see what,s on the horizon, ... so they can continue to offer an affordable pharmacy ...
(Date:5/21/2013)... , May 21, 2013  AcelRx Pharmaceuticals, ... specialty pharmaceutical company focused on the development ... treatment of acute and breakthrough pain, today ... placebo-controlled Phase 3 study of its investigational ... (NanoTab System), the primary efficacy endpoint was ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... REDWOOD CITY, Calif., May 6, 2011 AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today announced that Richard King, President and Chief Executive ... Research Conference at the San Francisco Ritz Carlton. The ...
... MIAMI, May 6, 2011 SaveRxCanada.com the premier Canadian pharmacy ... still purchase Canada drugs from a Canada pharmacy ... Canada drugs can be 85% less than the U.S. ... clientele since 2002. 2. Convenience – Many patients are ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference 2Canadian Pharmacy Intermediary's Top Reasons U.S. Customers Choose Canada Online Pharmacies Revealed by SaveRxCanada.com 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: